Limitations, agreements, and source contact

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas · Source last updated 2019-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

In Part A2, the study was open for the enrolment of infant participants of less than 12 months of age, however no participants were enrolled into this part.

point Of Contact

email

esi_medinfo@eisai.com

organization

Eisai, Inc.

phone

1-888-422-4743

title

Eisai Medical Services

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice